Latest News

*Number of shares following registration of share issue is corrected

Oslo, Norway, 15 December 2020: Reference is made to the stock exchange release by Photocure ASA ("Photocure" or the "Company") published on 3 December 2020 regarding registration of a share capital increase following the exercise of share options.

PRESS RELEASE – Oslo, Norway, 7 December, 2020: Photocure ASA (OSE:PHO) today announced new data and analyses presented at the 21^st Annual Meeting of the Society of Urologic Oncology (SUO). Presentations discussed the use of Blue Light Cystoscopy (BLC™) with Cysview^®, in particular the positive impact on patient outcomes in the surveillance setting without a significant impact on the cost of care, as well as the benefits of identifying early recurrences in high-risk NMIBC patients undergoing BCG treatment.

Oslo, Norway, 3 December 2020: Reference is made to the stock exchange release by Photocure ASA ("Photocure" or the "Company") published on 1 December 2020 regarding a share capital increase following the exercise of share options.

Oslo, Norway, 1 December 2020: Reference is made to the stock exchange release by Photocure ASA ("Photocure" or the "Company") published on 30 November 2020 regarding exercise of share options.

Oslo, Norway, 30 November 2020: Participants in Photocure ASA's ("Photocure" or the "Company") share option program have on 30 November 2020 exercised a total of 90,150 options distributed as follows:

Oslo, Norway, 11 November, 2020: Photocure ASA (OSE:PHO) today announces that its partner Asieris Pharmaceuticals has initiated the phase III clinical trial for APL-1702 (Cevira^®), triggering a USD 1.5 million milestone payment under the global licensing deal.

Oslo, Norway, 10 November 2020: Photocure ASA (OSE:PHO) today reported Hexvix^®/Cysview^® revenues of NOK 49.6 million in the third quarter of 2020 (Q3 2019: NOK 51.1), with the U.S. market continuing the Covid-19 rebound with a growth of 20%. Photocure has successfully launched the European Hexvix operations and reiterates the strong outlook and 2023 ambitions.

Oslo, Norway, 4 November 2020: Photocure ASA (Photocure, PHO: OSE) will announce the third quarter 2020 financial results on Tuesday 10 November 2020 at 07:00 CET and invites investors, analysts and the media to a presentation at 14:00 CET the same day.

PRESS RELEASE – Oslo, Norway, 16 October, 2020: Photocure ASA (OSE:PHO) today announces a highlight from the BLADDR 2020 congress, a poster presentation on new findings from the Nordic Flexible BLC registry, an ongoing prospective multicenter study. It demonstrates that flexible Blue Light Cystoscopy helped resolve a substantial amount of cases by complete removal on-site or direct referral to intravesical treatment, providing increased efficacy to manage non-muscle-invasive bladder cancer (NMIBC) in the office setting.

Oslo, Norway, 5 October 2020: Photocure ASA (OSE:PHO) today announces that the European Patent Office (EPO) has granted patent EP 2983780 covering the commercial Cevira^® device in Europe until 2034.

Oslo, Norway, 1 October 2020: Photocure ASA (OSE:PHO) today announces the commencement of the sales, marketing and distribution of Hexvix^® in the European markets formerly operated by Ipsen Pharma SAS (Ipsen). The successful transition and launch of European Hexvix operations creates a robust platform for accelerated growth and expansion for Photocure.

Oslo, Norway, 15 September 2020 - The board of directors in Photocure ASA (the "Company") (OSE: PHO) has granted share options to employees.

Oslo, Norway, 3 September 2020: Reference is made to the stock exchange announcement by Photocure ASA ("Photocure") published 31 August 2020 regarding a share capital increase following the exercise of employee share options.

Oslo, Norway, 31 August 2020.

Participants in Photocure ASA's ("Photocure") share option program have on 31 August 2020 exercised a total of 17,366 options, distributed as follows:

Photocure's CEO Dan Schneider and CFO Erik Dahl will continue their dialogue with stakeholders at a live Q&A session on Wednesday, August 26, 2020, organized by Xtrainvestor on their facebook channel.

Oslo, Norway, 18 August 2020: Photocure ASA (OSE:PHO) reported Hexvix^®/Cysview^® revenues of 53.5 million in the second quarter of 2020 (Q2 2019: NOK 52.1), corresponding to growth of three per cent, despite a significant Covid-19 impact in the beginning of the quarter in the U.S. market before a strong recovery towards the end of the period. The company has entered into an agreement with Ipsen Pharma SAS (Ipsen) for the return of Hexvix sales, marketing and distribution rights from the fourth quarter of 2020 and sees significant growth opportunities in Europe. The agreement is expected to be EBITDA accretive from full-year 2021 and beyond.

Oslo, Norway, 13 August 2020: Photocure ASA (Photocure, PHO: OSE) will announce the second quarter and first half year 2020 financial results on Tuesday 18 August 2020 at 07:00 CET and invites investors, analysts and the media to a presentation at 14:00 CET the same day.

Oslo, Norway, 13 August 2020: Photocure ASA (OSE: PHO), today announced the appointment of Genotests SpA as the exclusive distributor for the commercialization of Hexvix^® in Chile.